Presentation and immunogenicity of prophylactic RNA Hepatitis C Virus genotype 4 vaccine by bio-informatics | ||||
| International Journal of Health Sciences (Egypt) | ||||
| Articles in Press, Accepted Manuscript, Available Online from 02 August 2023 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijhegy.2023.222007.1031 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed M Kassab  
| ||||
| Instructor of microbiology,immunology,faculty of pharmacy,Cairo university,Egypt Specialist of pharmacology, toxicology and clinical pharmacy. | ||||
| Abstract | ||||
| Background: Hepatitis C is currently a hazardous worldwide illness. Infection is usually restricted to the hepatocytes. Because of the rapid mutation rate of the Hepatitis C virus, immunity lasts a short time and reinfection occurs (HCV). Infected individuals suffer chronic hepatitis, cirrhosis, and liver cancer. It is believed that around 2% of the world's population is afflicted with HCV, a blood-borne and sexually transmitted illness. At the moment, two types of HCV vaccines are being studied: preventive (to avoid infection) and therapeutic (to treat and prevent disease progression to cirrhosis and liver cancer). Methodology: In this investigation, bioinformatics were utilized to create lipid nanoparticles RNA vaccines of envelop( E1, E2) integral type 1 trans-membrane glycoproteins and integral nucleocapsid( C)proteins. The particle size of the lipid nanoparticles vaccine delivery method was designed to be around 60 nm. Immunogenicity tests were performed in animal testing stage followed by clinical trials phases 1/2. Results: The vaccine demonstrated 67% effectiveness in preclinical testing and 61% efficacy in human clinical trials stages 1 and 2. It had higher biological activity and fewer adverse effects than other conventional vaccinations currently being tested in clinical studies. The effectiveness was long-lasting due to the induction of potent neutralizing antibodies E2, C, and moderate cell-mediated immunity against these structural proteins, particularly the immunodominant C protein. Conclusion: In the present study, the preventive HCV genotype 4 vaccination proved efficacious with long lasting effect. | ||||
| Keywords | ||||
| Hepatitis C; vaccine; recombinant mRNA; genotype 4 | ||||
|
Statistics Article View: 31 |
||||
